BR112020016205A2 - Formas cocristalinas de prolina e de análogo de novobiocina - Google Patents

Formas cocristalinas de prolina e de análogo de novobiocina Download PDF

Info

Publication number
BR112020016205A2
BR112020016205A2 BR112020016205-1A BR112020016205A BR112020016205A2 BR 112020016205 A2 BR112020016205 A2 BR 112020016205A2 BR 112020016205 A BR112020016205 A BR 112020016205A BR 112020016205 A2 BR112020016205 A2 BR 112020016205A2
Authority
BR
Brazil
Prior art keywords
proline
cocrystal
powder
peaks
ethyl
Prior art date
Application number
BR112020016205-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Xin Jiang
John Allen Walling
Melanie J. Bevill
Christopher S. Seadeek
Jared P. Smit
Original Assignee
Reata Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals, Inc. filed Critical Reata Pharmaceuticals, Inc.
Publication of BR112020016205A2 publication Critical patent/BR112020016205A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/207Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • C07H1/06Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112020016205-1A 2018-02-07 2019-02-01 Formas cocristalinas de prolina e de análogo de novobiocina BR112020016205A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862627570P 2018-02-07 2018-02-07
US62/627,570 2018-02-07
PCT/US2019/016304 WO2019156907A1 (en) 2018-02-07 2019-02-01 Co-crystal forms of a novobiocin analog and proline

Publications (1)

Publication Number Publication Date
BR112020016205A2 true BR112020016205A2 (pt) 2020-12-15

Family

ID=65444361

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020016205-1A BR112020016205A2 (pt) 2018-02-07 2019-02-01 Formas cocristalinas de prolina e de análogo de novobiocina

Country Status (19)

Country Link
US (3) US10717755B2 (https=)
EP (1) EP3749675B1 (https=)
JP (3) JP2021512910A (https=)
KR (2) KR20240155354A (https=)
CN (2) CN112020506B (https=)
AR (1) AR114245A1 (https=)
AU (3) AU2019217821B2 (https=)
BR (1) BR112020016205A2 (https=)
CA (2) CA3226385A1 (https=)
CL (2) CL2020002051A1 (https=)
CO (1) CO2020009761A2 (https=)
EA (1) EA202091885A1 (https=)
IL (2) IL276583B2 (https=)
MX (2) MX2020008326A (https=)
MY (1) MY209803A (https=)
PE (1) PE20211446A1 (https=)
SG (1) SG11202007530XA (https=)
TW (2) TWI797249B (https=)
WO (1) WO2019156907A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3749675B1 (en) 2018-02-07 2025-12-31 Reata Pharmaceuticals, Inc. CO-CRISTALLIN FORMS OF A NOVOBIOCIN AND PROLINE ANALOGUE
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN115181146B (zh) * 2021-04-02 2024-06-04 浙江普洛家园药业有限公司 一种新生霉素的提取工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029369B2 (en) * 2010-09-23 2015-05-12 Nuformix Limited Aprepitant L-proline composition and cocrystal
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
CA2892832C (en) * 2011-11-25 2020-04-14 Nuformix Technologies Limited Aprepitant l-proline solvates - compositions and cocrystals
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
SMT201900660T1 (it) * 2012-02-09 2020-01-14 Univ Kansas Inibitori c-terminali di hsp90
EP2890704B1 (en) * 2012-08-31 2018-02-28 Novartis AG 2'-ethynyl nucleoside derivatives for treatment of viral infections
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
MX388516B (es) * 2014-06-24 2025-03-20 Univ Kansas Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70.
KR20170060035A (ko) * 2014-09-30 2017-05-31 지앙수 헨그루이 메디슨 컴퍼니 리미티드 나트륨 글루코스 공동운반체 2 억제제의 l- 프롤린 화합물, 및 l- 프롤린 화합물의 모노하이드레이트 및 결정
EP3749675B1 (en) 2018-02-07 2025-12-31 Reata Pharmaceuticals, Inc. CO-CRISTALLIN FORMS OF A NOVOBIOCIN AND PROLINE ANALOGUE

Also Published As

Publication number Publication date
TWI868593B (zh) 2025-01-01
IL276583A (en) 2020-09-30
JP2026012851A (ja) 2026-01-27
US11401294B2 (en) 2022-08-02
EA202091885A1 (ru) 2021-01-15
TWI797249B (zh) 2023-04-01
AU2022283638B2 (en) 2024-07-25
CA3226385A1 (en) 2019-08-15
CN112020506A (zh) 2020-12-01
IL315865A (en) 2024-11-01
US20190241599A1 (en) 2019-08-08
MY209803A (en) 2025-08-05
MX2022012856A (es) 2022-11-30
SG11202007530XA (en) 2020-09-29
CN112020506B (zh) 2024-10-11
AU2022283638A1 (en) 2023-02-02
PE20211446A1 (es) 2021-08-05
MX2020008326A (es) 2020-09-28
CL2022003784A1 (es) 2023-06-09
CL2020002051A1 (es) 2021-02-19
NZ767558A (en) 2024-11-29
AR114245A1 (es) 2020-08-12
IL276583B1 (en) 2024-11-01
JP2021512910A (ja) 2021-05-20
EP3749675B1 (en) 2025-12-31
US20240043465A1 (en) 2024-02-08
KR102718111B1 (ko) 2024-10-17
US10717755B2 (en) 2020-07-21
WO2019156907A1 (en) 2019-08-15
CA3090646C (en) 2024-02-27
TW201945381A (zh) 2019-12-01
JP2024001167A (ja) 2024-01-09
AU2019217821B2 (en) 2022-09-08
AU2024227646A1 (en) 2024-11-14
CO2020009761A2 (es) 2020-10-30
CN118894894A (zh) 2024-11-05
KR20200141985A (ko) 2020-12-21
TW202323267A (zh) 2023-06-16
AU2019217821A1 (en) 2020-09-24
EP3749675A1 (en) 2020-12-16
KR20240155354A (ko) 2024-10-28
CA3090646A1 (en) 2019-08-15
US20200347088A1 (en) 2020-11-05
IL276583B2 (en) 2025-03-01
TW202510893A (zh) 2025-03-16

Similar Documents

Publication Publication Date Title
US20240043465A1 (en) Co-crystal forms of a novobiocin analog and proline
ES3053674T3 (en) Crystalline forms and methods of producing crystalline forms of a compound
ES2922158T3 (es) Compuestos cristalinos
US12479808B2 (en) Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
SA519401004B1 (ar) بلورات من مشتق أمين حلقي واستخدامها الصيدلاني
US11136332B2 (en) Morphic forms of marizomib and uses thereof
EP2078014A2 (en) Crystalline and amorphous forms of tiagabine
TWI915111B (zh) 新生黴素(novobiocin)類似物及脯胺酸之共晶型
EA049105B1 (ru) Формы сокристаллов аналога новобиоцина и пролина
HK40119275A (zh) 新生霉素类似物与脯氨酸的共晶体形式
EA043335B1 (ru) Формы сокристаллов аналога новобиоцина и пролина
WO2026024591A1 (en) Tryptamine prodrug solid forms
HK40069001A (en) Salt and crystal forms of an activin receptor-like kinase inhibitor
WO2016113242A1 (en) Di-pidotimod benzathine and solid forms thereof

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]